Table 1.
Clinical characteristics of patients with type 2 diabetes mellitus (T2DM) treated with SGLT2i
| Patient enrollment (n = 8992) | |
|---|---|
| Clinical characteristics | |
| Diabetes duration (year) | 8.6 ± 3.4 |
| Age (year) | 58.8 ± 11.3 |
| Female | 3864 (43) |
| Ischemic heart etiology | 633 (7) |
| Hypertension | 6032 (67) |
| Dyslipidemia | 7026 (78) |
| Cerebral vascular accidents | 361 (4) |
| Congestive heart failure | 291 (3) |
| Peripheral artery disease | 74 (1) |
| Gout | 924 (10) |
| Malignancy | 734 (8) |
| Baseline body weight (BW) and BW change | |
| Baseline body weight (kg) | 74.0 ± 15.1 |
| Baseline BMI (kg/m2) | 27.9 ± 4.7 |
| Body weight change (kg) | − 1.24 ± 2.83 |
| Body weight change (%) | − 1.65 ± 3.84 |
| Baseline laboratory data | |
| HbA1c (%) | 8.9 ± 1.6 |
| eGFR (ml/min/1.73 m2) | 93.3 ± 22.0 |
| Triglycerides (mg/dL) | 180.3 ± 204.7 |
| LDL (mg/dL) | 92.5 ± 29.7 |
| HDL (mg/dL) | 43.9 ± 11.2 |
| Uric acid (mg/dL) | 5.7 ± 1.4 |
| Urine ACR (mg/g) | 236.9 ± 787.8 |
| Baseline medications | |
| Anti-platelet agent | 2809 (31) |
| Statin | 5703 (63) |
| ACEI or ARB | 5371 (60) |
| Use of diuretics | 787 (9) |
| Anti-diabetic agent | |
| SU | 6203 (69) |
| Metformin | 8229 (92) |
| Glinide | 297 (3) |
| DPP4i | 4564 (51) |
| Glitazone | 2340 (26) |
| Acarbose | 1955 (22) |
| Insulin | 1736 (19) |
| GLP1 agonist | 84 (1) |
Data are expressed as mean ± standard deviation or number (%)
ACEI angiotensin-converting enzyme inhibitor, ACR albumin to creatinine ratio, ARB angiotensin receptor blocker, BMI body mass index, DPP4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular filtration rate, GLP1 glucagon-like peptide 1, HBA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, SGLT2i sodium–glucose co-transporter-2 inhibitor, SU sulfonylurea